The J.P. Morgan Healthcare Conference, the biggest week of the year for investors inside biotechnology sector, hadn’t even officially started off when word of a multibillion-dollar acquisition broke: Celgene can be spending at least $1.1 billion, in addition to potentially almost $6 billion more, to buy Impact Biomedicines.
of which’s business as usual for the summit, which draws thousands of investors, executives in addition to analysts to San Francisco each January. More than 450 companies are scheduled to present at the conference, setting the stage for the year ahead.
On everyone’s minds This specific week: Will the U.S. tax overhaul spur acquisitions? in addition to will the president Again attack the industry for its pricing practices?
Sunday afternoon came news of the former: Celgene’s acquisition of Impact Biomedicines, a private biotechnology company with an experimental medicine for the bone marrow disorder myelofibrosis. Celgene can be paying $1.1 billion in cash, with almost $6 billion more if Impact meets certain regulatory in addition to sales goals.
A deal to kick off the conference follows suit with previous years: in 2015, the weekend before the conference brought news of Shire’s $5.2 billion acquisition of NPS Pharma; in 2016, Shire’s $32 billion acquisition of Baxalta. in addition to last year, the news held at least until the official start to the conference Monday morning: Takeda’s $5.2 billion purchase of Ariad.
M&A isn’t the only topic of discussion This specific week. The summit can be also a key time for companies to report results in addition to provide forecasts for the year ahead; already the weekend brought news by Exact Sciences, Alnylam in addition to Sanofi. Analysts are also expecting updates early inside week by Regeneron, Vertex in addition to Acorda, just a few among the onslaught of which begins Monday morning.
Finally, investors are hoping the week remains quieter on at least one front: of which of President Donald Trump. This specific was on the third day of the J.P. Morgan conference last year of which Trump said in a speech of which the pharmaceutical industry can be “getting away with murder” when This specific comes to the prices of medicines, driving the IBB biotech ETF down almost 3 percent.
Despite Trump’s rhetoric, in addition to investor fears, 2017 brought little inside way of government action on drug prices, in addition to biotech stocks, despite a rocky second half, ended the year up about 20 percent.